Neuraminidase inhibitors for treatment of human and avian strain influenza: A comparative modeling study

Journal of Theoretical Biology

Volumn 269, Issue 1, 2011, Pages 234-244

  Dobrovolny, Hana M ^a   Gieschke, Ronald ^b   Davies, Brian E ^c   Jumbe, Nelson L ^b   Beauchemin, Catherine A A ^a  

^a RYERSON UNIVERSITY   (Canada)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c HOFFMANN LA ROCHE INC   (United States)

Author keywords

Antiviral treatment; Avian influenza; Infectious disease; Mathematical modeling; Neuraminidase inhibitor

Indexed keywords

SIALIDASE INHIBITOR;

AVIAN INFLUENZA; COMPARATIVE STUDY; DISEASE TREATMENT; INFECTIOUS DISEASE; INHIBITOR; MODELING; NUMERICAL MODEL;

ANTIVIRAL THERAPY; ARTICLE; AVIAN INFLUENZA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; INFLUENZA; MATHEMATICAL MODEL; PRIORITY JOURNAL; SEASONAL INFLUENZA; THERAPY DELAY; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; ENZYME INHIBITORS; HUMANS; INFLUENZA IN BIRDS; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; NEURAMINIDASE; OSELTAMIVIR; VIRAL LOAD;

AVES; ORTHOMYXOVIRIDAE;

EID: 78149355232     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.10.017     Document Type: Article

References (71)

1. Baccam P., Beauchemin C., Macken C.A., Hayden F.G., Perelson A.S. Kinetics of influenza A virus infection in humans. J. Virol. 2006, 80(15):7590-7599.
2. Baz M., Abed Y., Simon P., Hamelin M., Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J. Infect. Dis. 2010, 201(5):740-745.
3. Beauchemin C.A., McSharry J.J., Drusano G.L., Nguyen J.T., Went G.T., Ribeiro R.M., Perelson A.S. Modeling amantadine treatment of influenza A virus in vitro. J. Theor. Biol. 2008, 254(2):439-451.
4. Bocharov G.A., Romanyukha A.A. Mathematical model of antiviral immune response III. Influenza A virus infection. J. Theor. Biol. 1994, 167(4):323-360.
5. Boltz D.A., Ilyushina N.A., Arnold C.S., Babu Y.S., Webster R.G., Govorkova E.A. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008, 80(May):150-157.
6. Boltz D.A., Rehg J.E., McClaren J., Webster R.G., Govorkova E.A. Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model. J. Infect. Dis. 2008, 197(May):1315-1327.
7. Bright R.A., Shay D.K., Shu B., Cox N.J., Klimov A.I. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. J. Am. Med. Assoc. 2006, 295(8):891-894.
8. Buchy P., Mardy S., Vong S., Toyoda T., Aubin J.-T., Miller M., Touch S., Sovann L., Dufourcq J.-B., Richner B., Tu P.V., Tien N.T.K., Lim W., Peiris J.M., Van der Werf S. Influenza A/H5N1 virus infection in humans in Cambodia. J. Clin. Virol. 2007, 39(April):164-168.
9. Burnham K.P., Anderson D.R. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach 2002, Springer-Verlag, New York, Inc., New York, USA. second ed.
10. Chan M., Cheung C., Chui W., Tsao S., Nicholls J., Chan Y., Chan R., Long H., Poon L., Guan Y., Peiris J. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir. Res. 2005, 6(November):135.
11. Cheung C.-L., Rayner J.M., Smith G.J.D., Wang P., Naipospos T.S.P., Zhang J., Yuen K.-Y., Webster R.G., Peiris J.S.M., Guan Y., Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193(June):1626-1629.
12. Cheung C.Y., Poon L.L.M., Lau A.S., Luk W., Lau Y.L., Shortridge K.F., Gordon S., Guan Y., Peiris J.S.M. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?. Lancet 2002, 360(December):1831-1837.
13. Claas E.C.J., Osterhaus A.D.M.E., van Beek R., de Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351(February):472-477.
14. Crystal R.G., West J.B. The Lung: Scientific Foundations 1991, Raven Press, Ltd., New York, USA.
15. de Jong M.D., Simmons C.P., Thanh T.T., Hien V.M., Smith G.J.D., Chau T.N.B., Hoang D.M., Chau N.V.V., Khanh T.H., Dong V.C., Qui P.T., Cam B.V., Ha D.Q., Guan Y., Peiris J.S.M., Chinh N.T., Hien T.T., Farrar J. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 2006, 12(10):1203-1207.
16. de Jong M.D., Thanh T.T., Khanh T.H., Hien V.M., Smith G.J., Chau N.V., Cam B.V., Qui P.T., Ha D.Q., Guan Y., Peiris J.M., Hien T.T., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353(25):2667-2672.
17. Dharan N.J., Gubareva L.V., Meyer J.J., Okomo-Adhiambo M., McClinton R.C., Marshall S.A., George K.S., Epperson S., Brammer L., Klimov A.I., Bresee J.S., Fry A.M. Local and systemic cytokine responses during experimental human influenza A virus infection. J. Am. Med. Assoc. 2009, 301(10):1034-1041.
18. Dobrovolny, H.M., Baron, M.J., Gieschke, R., Davies, B.E., Jumbe, N.L., Beauchemin, C.A.A. Exploring cell tropism as a possible contributor to influenza infection severity. PLoS One, in press, doi:. http://10.1371/journal.pone.0013811.
19. Doherty P.C., Turner S.J., Webby R.G., Thomas P.G. Influenza and the challenge for immunology. Nat. Immunol. 2006, 7(5):449-455.
20. Duwe S., Schweiger B. A new and rapid genotypic assay for the detection of neuraminidase inhibitor resistant influenza A viruses of subtype H1N1, H3N2, and H5N1. J. Virol. Methods 2008, 153(July):134-141.
21. Fritz R.S., Hayden F.G., Calfee D.P., Cass L.M.R., Peng A.W., Alvord W.G., Strober W., Straus W. Nasal cytokine and chemokine response in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J. Infect. Dis. 1999, 180:586-593.
22. Gambotto A., Barratt-Boyes S.M., de Jong M.D., Neumann G., Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008, 371(April):1464-1475.
23. Govorkova E.A., Ilyushina N.A., Boltz D.A., Douglas A., Yilmaz N., Webster R.G. Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus. Antimicrob. Agents Chemother. 2007, 51(4):1414-1424.
24. Govorkova E.A., Leneva I.A., Goloubeva O.G., Bush K., Webster R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2 and other avian influenza viruses. Antimicrob. Agents Chemother. 2001, 45(10):2723-2732.
25. Gubareva L.V., McCullers J.A., Bethell R.C., Webster R.G. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J. Infect. Dis. 1998, 178(6):1592-1596.
26. Handel A., Longini I.M., Antia R Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread. PLoS Comput. Biol. 2007, 3(12):2456-2464.
27. Handel A., Longini I.M., Antia R. Towards a quantitative understanding of the within-host dynamics of influenza A infections. J. R. Soc. Interface 2010, 7(42):35-47.
28. Hayden F.G., Fritz R.S., Lobo M.C., Alvord W.G., Strober W., Straus S.E. Local and systemic cytokine responses during experimental human influenza A virus infection. J. Clin. Invest. 1998, 101(3):643-649.
29. Hayden F.G., Treanor J.J., Betts R.F., Lobo M., Esinhart J.D., Hussey E.K. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J. Am. Med. Assoc. 1996, 275(4):295-299.
30. Hayden F.G., Treanor J.J., Fritz R.S., Lobo M., Betts R.F., Miller M., Kinnersley N., Mills R.G., Ward P., Straus S.E. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. J. Am. Med. Assoc. 1999, 282(13):1240-1246.
31. He G., Qiao J., Dong C., He C., Zhao L., Tian Y. Amantadine-resistance among H5N1 avian influenza viruses isolated in northern China. Antiviral Res. 2008, 77:72-76.
32. Hien N.D., Ha N.H., Van N.T., Ha N.T.M., Lien T.T.M., Thai N.Q., Trang V.D., Shimbo T., Takahashi Y., Kato Y., Kawana A., Akita S., Kudo K. Human infection with highly pathogenic avian influenza virus (H5N1) in Northern Vietnam, 2004-2005. Emerg. Infect. Dis. 2009, 15(1):19-23.
33. Hien T.T., Liem N.T., Dung N.T., San L.T., Mai P.P., van VinhChau N., Suu P.T., Dong V.C., Mai L.T.Q., Thi N.T., Khoa D.B., Phat L.P., Truong N.T., Long H.T., Tung C.V., Giang L.T., Tho N.D., Nga L.H., Tien N.T.K., San L.H., Tuan L.V., Dolecek C., Thanh T.T., de Jong M., Schultsz C., Cheng P., Lim W., Horby P., Farrar J. Avian influenza A (H5N1) in 10 patients in Vietnam. N. Engl. J. Med. 2004, 350(12):1179-1188.
34. Holford N., Sheiner L. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 1981, 6(6):429-453.
35. Hsieh Y., Wu T., Liu D., Shao P., Chang L., Lu C., Lee C., Huang F., Huang L. Influenza pandemics: past, present and future. J. Formos. Med. Assoc. 2006, 105(1):1-6.
36. Hurt A., Selleck P., Komadina N., Shaw R., Brown L., Barr I. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res. 2007, 73:228-231.
37. Ibrecevic A., Pekosz A., Walter M.J., Newby C., Battaile J.T., Brown E.G., Holtzman M.J., Brody S.L. Influenza virus receptor specificity and cell tropism in mouse and human airway epithelial cells. J. Virol. 2006, 80(15):7469-7480.
38. Kaiser L., Fritz R.S., Straus S.E., Gubareva L., Hayden F.G. Symptom pathogenesis during acute influenza: Interleukin-6 and other cytokine responses. J. Med. Virol. 2001, 64(3):262-268.
39. Kandun I.N., Tresnaningsih E., Purba W.H., Lee V., Samaan G., Harun S., Soni E., Septiawati C., Setiawati T., Sariwati E., Wandra T. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet 2008, 372(9640):744-749.
40. Kobasa D., Kawaoka Y. Emerging influenza viruses: past and present. Curr. Mol. Med. 2005, 5(8):791-803.
41. Kogure T., Suzuki T., Takahashi T., Miyamoto D., Hidari K.I., Guo C.-T., Ito T., Kawaoka Y., Suzuki Y. Human trachea primary epithelial cells express both sialyl(α2-3)Gal receptor for human parainfluenza virus type 1 and avian influenza viruses, and sialyl(α2-6)Gal receptor for human influenza virus. Glycoconj. J. 2006, 23(1-2):101-106.
42. Lau L.L.H., Cowling B.J., Fang V.J., Chan K., Lau E.H.Y., Lipsitch M., Cheng C.K.Y., Houck P.M., Uyeki T.M., Peiris J.S.M., Leung G.M. Viral shedding and clinical illness in naturally acquired influenza virus infections. J. Infect. Dis. 2010, 201(10):1509-1516.
43. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H.L., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Isolation of drug-resistant H5N1 virus. Nature 2005, 437(October):1108.
44. Leneva I.A., Goloubeva O., Fenton R.J., Tisdale M., Webster R.G. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob. Agents Chemother. 2001, 45(4):1216-1224.
45. Leneva I.A., Roberts N., Govorkova E.A., Goloubeva O.G., Webster R.G. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res. 2000, 48(2):101-115.
46. Maines T.R., Chen L.-M., Matsuoka Y., Chen H., Rowe T., Ortin J., Falcon A., Hien N.T., Mai L.Q., Sedyaningsih E.R., Harun S., Tumpey T.M., Donis R.O., Cox N.J., Subbarao K., Katz J.M. Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc. Natl. Acad. Sci. USA 2006, 103(32):12121-12126.
47. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.-D. Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc. Natl. Acad. Sci. USA 2004, 101(13):4620-4624.
48. Matrosovich M.N., Matrosovich T.Y., Uhlendorff J., Garten W., Klenk H.-D. Avian-virus-like receptor specificity of the hemagglutinin impedes influenza virus replication in cultures of human airway epithelium. Virology 2007, 361(2):384-390.
49. McGeer, A., Green, K.A., Plevneshi, A., Shigayeva, A., Siddiqi, N., Raboud, J., Low, D.E., for the Toronto Invasive Bacterial Diseases Network, 2007. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 45 (12), 1568-1575.
50. Miao H., Hollenbaugh J.A., Zand M.S., Holden-Wiltse J., Mosmann T.R., Perelson A.S., Wu H., Topham D.J. Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J. Virol. 2010, 84(13):6687-6698.
51. Miao, H., Xia, X., Perelson, A.S., Wu, H., On identifiability of nonlinear ODE models and applications in viral dynamics. SIAM Rev., in press. Available at: http://www.urmc.rochester.edu/biostat/people/faculty/wusite/documents/2010-7.pdf.
52. Moghadas S.M. Management of drug resistance in the population: influenza as a case study. Proc. R. Soc. B 2008, 275:1163-1169.
53. Oner A.F., Bay A., Arslan S., Akdeniz H., Sahin H.A., Cesur Y., Epcacan S., Yilmaz N., Deger I., Kizilyildiz B., Karsen H., Ceyhan M. Avian influenza A (H5N1) infection in eastern Turkey in 2006. N. Engl. J. Med. 2006, 355(21):2179-2185.
54. Pekosz A., Newby C., Bose P.S., Lutz A. Sialic acid recognition is a key determinant of influenza a virus tropism in murine trachea epithelial cell cultures. Virology 2009, 386(February):61-67.
55. Perrone L.A., Plowden J.K., García-Sastre A., Katz J.M., Tumpey T.M. H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog. 2008, 4(8):1-11.
56. Rameix-Welti M.A., van der Werf S., Naffakh N. Sensitivity of H5N1 influenza viruses to oseltamivir: an update. Future Virol. 2008, 3(2):157-165.
57. Schunemann H.J., Hill S.R., Kakad M., Bellamy R., Uyeki T.M., Hayden F.G., Yazdanpanah Y., Beigel J., Chotpitayasunondh T., Del Mar C., Farrar J., Hien T.T., Ozbay B., Sugaya N., Fukuda K., Shindo N., Stockman L., Vist G.E., Croisier A., Nagjdaliyev A., Roth C., Thomson G., Zucker H., Oxman A.D. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect. Dis. 2007, 7(January):21-31.
58. Seo S.H., Hoffmann E., Webster R.G. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat. Med. 2002, 8(9):950-954.
59. Seo S.H., Webster R.G. Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J. Virol. 2002, 76(3):1071-1076.
60. Stevens J., Blixt O., Chen L.-M., Donis R.O., Paulson J.C., Wilson I.A. Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J. Mol. Biol. 2008, 381(April):1382-1394.
61. Stittelaar K., Tisdale M., van Amerongen G., van Lavieren R., Pistoor F., Simon J., Osterhaus A. Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res. 2008, 80(July):225-228.
62. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(January):393-396.
63. Thompson C.I., Barclay W.S., Zambon M.C., Pickles R.J. Infection of human airway epithelium by human and avian strains of influenza A virus. J. Virol. 2006, 80(16):8060-8068.
64. Tumpey T.M., Maines T.R., Hoeven N.V., Glaser L., Solorzano A., Pappas C., Cox N.J., Swayne D.E., Palese P., Katz J.M., Garcia-Sastre A. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science 2007, 315(February):655-659.
65. Uiprasertkul M., Kitphati R., Piuthavathana P., Kriwong R., Kongchanagul A., Ungchusak K., Angkasekwinai S., Chokephaibulkit K., Srisook K., Vanprapar N., Auewarakul P. Apoptosis and pathogenesis of avian influenza a (h5n1) virus in humans. Emerg. Infect. Dis. 2007, 13(5):708-712.
66. van Riel D., Munster V.J., de Wit E., Rimmelzwaan G.F., Fouchier R.A., Osterhaus A.D., Kuiken T. H5N1 virus attachment to lower respiratory tract. Science 2006, 312(5772):399. (originally published in Science Express on 23 March 2006).
67. Whitley R.J., Hayden F.G., Reisinger K.S., Young N., Dutkowski R., Ipe D., Mills R.G., Ward P. Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. 2001, 20(2):127-133.
68. Yen H.-L., Herlocher L.M., Hoffmann E., Matrosovich M.N., Monto A.S., Webster R.G., Govorkova E.A. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob. Agents Chemother. 2005, 49(10):4075-4084.
69. Yen H.-L., Ilyushina N.A., Salomon R., Hoffmann E., Webster R.G., Govorkova E.A. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J. Virol. 2007, 81(22):12418-12426.
70. Yun N.E., Linde N.S., Zacks M.A., Barr I.G., Hurt A.C., Smith J.N., Dziuba N., Holbrook M.R., Zhang L., Kilpatrick J.M., Arnold C.S., Paessler S. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus A/Vietnam/1203/04 (H5N1). Virology 2008, 374(January):198-209.
71. Zheng B.-J., Chan K.-W., Lin Y.-P., Zhao G.-Y., Chan C., Zhang H.-J., Chen H.-L., Wong S.S.Y., Lau S.K.P., Woo P.C.Y., Chan K.-H., Jin D.-Y., Yuen K.-Y. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. 2008, 105(23):8091-8096.